{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:40:58Z","timestamp":1780666858367,"version":"3.54.1"},"reference-count":199,"publisher":"Elsevier","isbn-type":[{"value":"9780128174777","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["301465\/2017-7"],"award-info":[{"award-number":["301465\/2017-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.acc.2019.04.002","type":"book-chapter","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:15:57Z","timestamp":1559121357000},"page":"105-140","source":"Crossref","is-referenced-by-count":13,"title":["Lipid trafficking in cardiovascular disease"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2019.04.002_bb0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamacardio.2016.1326","article-title":"Recent trends in cardiovascular mortality in the United States and public health goals","volume":"1","author":"Sidney","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2019.04.002_bb0020","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group SR","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrm2336","article-title":"Cellular cholesterol trafficking and compartmentalization","volume":"9","author":"Ikonen","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1172\/JCI0216452","article-title":"Consequences of cellular cholesterol accumulation: basic concepts and physiological implications","volume":"110","author":"Tabas","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2019.04.002_bb0040","doi-asserted-by":"crossref","first-page":"11664","DOI":"10.1073\/pnas.0404766101","article-title":"How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids","volume":"101","author":"Lange","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.acc.2019.04.002_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.devcel.2016.09.030","article-title":"Lipids and their trafficking: an integral part of cellular organization","volume":"39","author":"Jackson","year":"2016","journal-title":"Dev. Cell"},{"key":"10.1016\/bs.acc.2019.04.002_bb0050","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature04399","article-title":"Role of cholesterol and lipid organization in disease","volume":"438","author":"Maxfield","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2019.04.002_bb0055","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1021\/bi0269207","article-title":"Expression of scavenger receptor BI facilitates sterol movement between the plasma membrane and the endoplasmic reticulum in macrophages","volume":"42","author":"Huang","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/bs.acc.2019.04.002_bb0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2019.04.002_bb0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2019.04.002_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.269","article-title":"Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts","volume":"41","author":"Aulchenko","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.acc.2019.04.002_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCGENETICS.108.773168","article-title":"Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication","volume":"1","author":"Chasman","year":"2008","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/bs.acc.2019.04.002_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.acc.2019.04.002_bb0085","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1253\/circj.CJ-10-0353","article-title":"A genome-wide association study of hypertension-related phenotypes in a Japanese population","volume":"74","author":"Hiura","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/bs.acc.2019.04.002_bb0090","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/ATVBAHA.108.172288","article-title":"Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13","volume":"28","author":"Burkhardt","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0095","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1126\/science.1090100","article-title":"Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays","volume":"302","author":"Johnson","year":"2003","journal-title":"Science"},{"key":"10.1016\/bs.acc.2019.04.002_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/CIRCULATIONAHA.108.773267","article-title":"Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin","volume":"118","author":"Medina","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2019.04.002_bb0105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-2275(20)37214-X","article-title":"Human lysosomal acid lipase\/cholesteryl ester hydrolase and human gastric lipase: identification of the catalytically active serine, aspartic acid, and histidine residues","volume":"38","author":"Lohse","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00109-005-0001-9","article-title":"The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways","volume":"84","author":"Boadu","year":"2006","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/bs.acc.2019.04.002_bb0120","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa054699","article-title":"Effect of ACAT inhibition on the progression of coronary atherosclerosis","volume":"354","author":"Nissen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency\u2014an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0130","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","article-title":"Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease","volume":"351","author":"Zanoni","year":"2016","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/bs.acc.2019.04.002_bb0135","first-page":"125","article-title":"Lysosomal acid lipase deficiency: diagnosis and treatment of Wolman and cholesteryl ester storage diseases","volume":"12","author":"Porto","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/bs.acc.2019.04.002_bb0140","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","article-title":"Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease","volume":"58","author":"Bernstein","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.26366","article-title":"Therapy for lysosomal acid lipase deficiency: replacing a missing link","volume":"58","author":"Grabowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/bs.acc.2019.04.002_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01805475","article-title":"Plasma lipids and lipoproteins of a patient with cholesteryl ester storage disease","volume":"8","author":"Kostner","year":"1985","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.acc.2019.04.002_bb0155","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1161\/ATVBAHA.113.302426","article-title":"Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia","volume":"33","author":"Stitziel","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/2213988501711010001","article-title":"Targeting wolman disease and cholesteryl ester storage disease: disease pathogenesis and therapeutic development","volume":"11","author":"Aguisanda","year":"2017","journal-title":"Curr. Chem. Genom. Transl. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0165","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of sebelipase alfa in Lysosomal acid Lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-511X-4-26","article-title":"Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease","volume":"4","author":"Tadiboyina","year":"2005","journal-title":"Lipids Health Dis."},{"key":"10.1016\/bs.acc.2019.04.002_bb0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF01799650","article-title":"Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin","volume":"15","author":"Yokoyama","year":"1992","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.acc.2019.04.002_bb0180","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-2275(20)41416-6","article-title":"Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy","volume":"33","author":"Levy","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ymgme.2012.03.012","article-title":"Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update","volume":"106","author":"Patterson","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.acc.2019.04.002_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","article-title":"Types A and B niemann-pick disease","volume":"120","author":"Schuchman","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.acc.2019.04.002_bb0195","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.90926.2008","article-title":"Acyl-coenzyme A: cholesterol acyltransferases","volume":"297","author":"Chang","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2019.04.002_bb0200","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev.biochem.66.1.613","article-title":"Acyl-coenzyme A: cholesterol acyltransferase","volume":"66","author":"Chang","year":"1997","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1042\/BJ20050428","article-title":"Investigating the allosterism of acyl-CoA:cholesterol acyltransferase (ACAT) by using various sterols: in vitro and intact cell studies","volume":"391","author":"Liu","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/bs.acc.2019.04.002_bb0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbalip.2004.01.008","article-title":"The influence of the acyl-CoA:cholesterol acyltransferase-1 gene (\u221277G-->A) polymorphisms on plasma lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects","volume":"1682","author":"Ohta","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.acc.2019.04.002_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-511X-11-9","article-title":"Sex-specific association of ACAT-1 rs1044925 SNP and serum lipid levels in the hypercholesterolemic subjects","volume":"11","author":"Wu","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/bs.acc.2019.04.002_bb0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2005.08.005","article-title":"ACAT1 deficiency increases cholesterol synthesis in mouse peritoneal macrophages","volume":"186","author":"Dove","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0225","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.3390\/ijms15033546","article-title":"Association between single nucleotide polymorphism rs1044925 and the risk of coronary artery disease and ischemic stroke","volume":"15","author":"Wu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2019.04.002_bb0230","doi-asserted-by":"crossref","first-page":"89055","DOI":"10.18632\/oncotarget.21649","article-title":"ACAT-1 gene polymorphism is associated with increased susceptibility to coronary artery disease in Chinese Han population: a case-control study","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2019.04.002_bb0235","first-page":"6287","article-title":"Human acetyl-CoA acetyltransferase-2 (ACAT-2) gene was associated with hyperlipidemia in han chinese population: a case-control study","volume":"9","author":"Abudoukelimu","year":"2016","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5551\/jat.10.32","article-title":"Effects of a new single-nucleotide polymorphism in the Acyl-CoA: cholesterol acyltransferase-2 gene on plasma lipids and apolipoproteins in patients with hyperlipidemia","volume":"10","author":"Katsuren","year":"2003","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2019.04.002_bb0245","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.atherosclerosis.2006.05.048","article-title":"A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels","volume":"191","author":"Ikenoya","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0250","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/01.CIR.103.21.2604","article-title":"Acyl-CoA: cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"103","author":"Kusunoki","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2019.04.002_bb0255","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1073\/pnas.0336398100","article-title":"Deficiency of acyl CoA: cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice","volume":"100","author":"Willner","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.acc.2019.04.002_bb0260","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000112634","article-title":"Statin therapy alone and in combination with an acyl-CoA: cholesterol O-acyltransferase inhibitor on experimental atherosclerosis","volume":"36","author":"Worthley","year":"2007","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/bs.acc.2019.04.002_bb0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1527-3466.2003.tb00104.x","article-title":"Pharmacology of the ACAT inhibitor avasimibe (CI-1011)","volume":"21","author":"Llaverias","year":"2003","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/bs.acc.2019.04.002_bb0270","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0021-9150(00)00615-8","article-title":"Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia","volume":"157","author":"Insull","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0275","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000084","article-title":"Intestinal lipid absorption and lipoprotein formation","volume":"25","author":"Hussain","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0280","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1194\/jlr.R083451","article-title":"Lipid transfer proteins in the assembly of apoB-containing lipoproteins","volume":"59","author":"Sirwi","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0285","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2019.04.002_bb0290","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/bs.acc.2019.04.002_bb0295","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.gendis.2017.09.002","article-title":"MTP genetic variants associated with non-alcoholic fatty liver in metabolic syndrome patients","volume":"4","author":"Gouda","year":"2017","journal-title":"Genes Dis."},{"key":"10.1016\/bs.acc.2019.04.002_bb0300","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1126\/science.174194","article-title":"Receptor-mediated control of cholesterol metabolism","volume":"191","author":"Brown","year":"1976","journal-title":"Science"},{"key":"10.1016\/bs.acc.2019.04.002_bb0305","article-title":"The LDL-Receptor and its molecular properties: from theory to novel biochemical and pharmacological approaches in reducing LDL-cholesterol","author":"Petroglou","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0310","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.biochem.74.082803.133354","article-title":"Structure and physiologic function of the low-density lipoprotein receptor","volume":"74","author":"Jeon","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0315","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MOL.0000000000000157","article-title":"The life cycle of the low-density lipoprotein receptor: insights from cellular and in-vivo studies","volume":"26","author":"Wijers","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0320","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0325","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MOL.0000000000000411","article-title":"News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1","volume":"28","author":"van de Sluis","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-016-0256-1","article-title":"The genetics and screening of familial hypercholesterolaemia","volume":"23","author":"Henderson","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/bs.acc.2019.04.002_bb0335","doi-asserted-by":"crossref","first-page":"40996","DOI":"10.1074\/jbc.M509394200","article-title":"The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits","volume":"280","author":"Garuti","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0340","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the international atherosclerosis society severe familial hypercholesterolemia panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2017.07.003","article-title":"The study of familial hypercholesterolemia in Italy: a narrative review","volume":"29","author":"Bertolini","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/bs.acc.2019.04.002_bb0350","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25","author":"Marais","year":"2004","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/bs.acc.2019.04.002_bb0355","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0360","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2019.04.002_bb0365","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/VHRM.S13496","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","author":"Hamilton-Craig","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/bs.acc.2019.04.002_bb0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0167-5273(02)00420-5","article-title":"Familial hypercholesterolemia\u2014improving treatment and meeting guidelines","volume":"89","author":"Hopkins","year":"2003","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/bs.acc.2019.04.002_bb0375","article-title":"Current role of lipoprotein apheresis in the treatment of high-risk patients","volume":"5","author":"Julius","year":"2018","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/bs.acc.2019.04.002_bb0380","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOL.0000000000000428","article-title":"Novel lipid modifying drugs to lower LDL cholesterol","volume":"28","author":"Cupido","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-med-051215-030943","article-title":"New therapeutic approaches for familial hypercholesterolemia","volume":"69","author":"Ajufo","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0390","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2019.04.002_bb0395","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2019.04.002_bb0400","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/iub.299","article-title":"Rare genetic causes of autosomal dominant or recessive hypercholesterolaemia","volume":"62","author":"Soutar","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/bs.acc.2019.04.002_bb0405","series-title":"Endotext","article-title":"The severe hypercholesterolemia phenotype: genes and beyond","author":"Pendyal","year":"2000"},{"key":"10.1016\/bs.acc.2019.04.002_bb0410","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1093\/hmg\/11.24.3019","article-title":"Molecular mechanisms of autosomal recessive hypercholesterolemia","volume":"11","author":"Wilund","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.acc.2019.04.002_bb0415","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1172\/JCI29415","article-title":"Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia","volume":"117","author":"Jones","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2019.04.002_bb0420","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacc.2017.11.028","article-title":"Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes","volume":"71","author":"D'Erasmo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/bs.acc.2019.04.002_bb0425","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/molecules22040589","article-title":"ABC transport proteins in cardiovascular disease-A brief summary","volume":"22","author":"Schumacher","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/bs.acc.2019.04.002_bb0430","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/01.RES.0000250171.54048.5c","article-title":"ATP-Binding cassette cholesterol transporters and cardiovascular disease","volume":"99","author":"Oram","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0435","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bbadis.2006.01.011","article-title":"ABC A-subfamily transporters: structure, function and disease","volume":"1762","author":"Kaminski","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.acc.2019.04.002_bb0440","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-319-09665-0_4","article-title":"Cholesterol efflux and reverse cholesterol transport","volume":"224","author":"Favari","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0445","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1194\/jlr.M300336-JLR200","article-title":"ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I","volume":"45","author":"Smith","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0450","doi-asserted-by":"crossref","first-page":"23742","DOI":"10.1074\/jbc.M102348200","article-title":"ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein","volume":"276","author":"Wang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0455","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M704590200","article-title":"Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles","volume":"282","author":"Vedhachalam","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0460","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/ATVBAHA.112.301195","article-title":"ABCA1 mediates unfolding of apolipoprotein AI N terminus on the cell surface before lipidation and release of nascent high-density lipoprotein","volume":"33","author":"Wang","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0465","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/biof.1187","article-title":"ABCA1 and nascent HDL biogenesis","volume":"40","author":"Wang","year":"2014","journal-title":"Biofactors"},{"key":"10.1016\/bs.acc.2019.04.002_bb0470","doi-asserted-by":"crossref","first-page":"12197","DOI":"10.1074\/jbc.M109.096933","article-title":"Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism","volume":"285","author":"Chung","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0475","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/CIRCULATIONAHA.108.812164","article-title":"Images in cardiovascular medicine. Tangier disease in severely progressive coronary and peripheral artery disease","volume":"119","author":"Sampietro","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2019.04.002_bb0480","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/01.ATV.0000148706.15947.8a","article-title":"Probucol inhibits ABCA1-mediated cellular lipid efflux","volume":"24","author":"Favari","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0485","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.110.009704","article-title":"Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport","volume":"124","author":"Yamamoto","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2019.04.002_bb0490","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1126\/science.290.5497.1771","article-title":"Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters","volume":"290","author":"Berge","year":"2000","journal-title":"Science"},{"key":"10.1016\/bs.acc.2019.04.002_bb0495","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI0216548","article-title":"Biliary cholesterol secretion by the twinned sterol half-transporters ABCG5 and ABCG8","volume":"110","author":"Wittenburg","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2019.04.002_bb0500","article-title":"Sitosterolemia","author":"Merkens","year":"1993"},{"key":"10.1016\/bs.acc.2019.04.002_bb0505","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1053\/j.gastro.2005.10.022","article-title":"Liver transplantation in a patient with sitosterolemia and cirrhosis","volume":"130","author":"Miettinen","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acc.2019.04.002_bb0510","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11883-014-0424-2","article-title":"Sitosterolemia: diagnosis, investigation, and management","volume":"16","author":"Escola-Gil","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/bs.acc.2019.04.002_bb0515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-physiol-021317-121550","article-title":"SR-B1: a unique multifunctional receptor for cholesterol influx and efflux","volume":"80","author":"Shen","year":"2018","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0520","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.271.5248.518","article-title":"Identification of scavenger receptor SR-BI as a high density lipoprotein receptor","volume":"271","author":"Acton","year":"1996","journal-title":"Science"},{"key":"10.1016\/bs.acc.2019.04.002_bb0525","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2017.01.034","article-title":"SR-BI as target in atherosclerosis and cardiovascular disease\u2014a comprehensive appraisal of the cellular functions of SR-BI in physiology and disease","volume":"258","author":"Hoekstra","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0530","doi-asserted-by":"crossref","first-page":"26338","DOI":"10.1074\/jbc.273.41.26338","article-title":"The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain","volume":"273","author":"Gu","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0535","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1194\/jlr.M700274-JLR200","article-title":"The roles of different pathways in the release of cholesterol from macrophages","volume":"48","author":"Adorni","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0540","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","article-title":"Genetic variant of the scavenger receptor BI in humans","volume":"364","author":"Vergeer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0545","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.acc.2019.04.002_bb0550","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/eurheartj\/ehy169","article-title":"Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease","volume":"39","author":"Helgadottir","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2019.04.002_bb0555","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00109-017-1575-8","article-title":"Mechanisms of foam cell formation in atherosclerosis","volume":"95","author":"Chistiakov","year":"2017","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/bs.acc.2019.04.002_bb0560","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.carpath.2012.06.006","article-title":"Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis","volume":"22","author":"Gimbrone","year":"2013","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0565","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOL.0000000000000279","article-title":"So much cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation","volume":"27","author":"Dubland","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0570","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1194\/jlr.R800066-JLR200","article-title":"The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges","volume":"50","author":"Greaves","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0575","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.2174\/1381612811319330005","article-title":"Fluid-phase pinocytosis of LDL by macrophages: a novel target to reduce macrophage cholesterol accumulation in atherosclerotic lesions","volume":"19","author":"Kruth","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/bs.acc.2019.04.002_bb0580","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/386292a0","article-title":"A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection","volume":"386","author":"Suzuki","year":"1997","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2019.04.002_bb0585","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3892\/mmr.2012.1170","article-title":"Synergistic effect of scavenger receptor A and low-density lipoprotein receptor on macrophage foam cell formation under inflammatory stress","volume":"7","author":"Su","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/bs.acc.2019.04.002_bb0590","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-90-481-8622-8_8","article-title":"Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis","volume":"51","author":"Miller","year":"2010","journal-title":"Subcell. Biochem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0595","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1210\/jc.2017-02243","article-title":"The effect of testosterone on cardiovascular biomarkers in the testosterone trials","volume":"103","author":"Mohler","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2019.04.002_bb0600","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1038\/emm.2014.38","article-title":"CD36, a scavenger receptor implicated in atherosclerosis","volume":"46","author":"Park","year":"2014","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0605","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ni.2639","article-title":"CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation","volume":"14","author":"Sheedy","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0610","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1194\/jlr.P700032-JLR200","article-title":"Chylomicron remnants are increased in the postprandial state in CD36 deficiency","volume":"50","author":"Masuda","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0615","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5551\/jat.10603","article-title":"Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases","volume":"19","author":"Yuasa-Kawase","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2019.04.002_bb0620","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jcmm.12689","article-title":"Macrophage-mediated cholesterol handling in atherosclerosis","volume":"20","author":"Chistiakov","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0625","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.yjmcc.2012.07.006","article-title":"Increased stability of phosphatase and tensin homolog by intermedin leading to scavenger receptor A inhibition of macrophages reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"53","author":"Dai","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/bj3340009","article-title":"Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor","volume":"334","author":"Yoshida","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/bs.acc.2019.04.002_bb0635","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(02)00236-X","article-title":"LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis","volume":"95","author":"Chen","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2019.04.002_bb0640","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/HCO.0000000000000410","article-title":"Small, dense LDL: an update","volume":"32","author":"Gerber","year":"2017","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0645","doi-asserted-by":"crossref","first-page":"698","DOI":"10.5551\/jat.7161","article-title":"Small dense LDL enhances THP-1 macrophage foam cell formation","volume":"18","author":"Tani","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2019.04.002_bb0650","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1161\/01.CIR.0000074207.85796.36","article-title":"Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease","volume":"107","author":"Chen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2019.04.002_bb0655","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5551\/jat.36327","article-title":"Association of the LOX-1 rs1050283 polymorphism with risk for atherosclerotic cerebral infarction and its effect on sLOX-1 and LOX-1 expression in a Chinese population","volume":"24","author":"Guo","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/bs.acc.2019.04.002_bb0660","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/eci.12013","article-title":"Oxidized LDL receptor 1 gene polymorphism in patients with metabolic syndrome","volume":"43","author":"Palmieri","year":"2013","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/bs.acc.2019.04.002_bb0665","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cca.2014.11.016","article-title":"LOX-1 in atherosclerotic disease","volume":"440","author":"Sawamura","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/bs.acc.2019.04.002_bb0670","article-title":"Molecular pathways underlying cholesterol homeostasis","volume":"10","author":"Silva Afonso","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/bs.acc.2019.04.002_bb0675","doi-asserted-by":"crossref","first-page":"44222","DOI":"10.1074\/jbc.M103942200","article-title":"The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells","volume":"276","author":"Ohtani","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0680","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.gene.2017.08.034","article-title":"Evaluation of the relationship between CD36 and MARCO single-nucleotide polymorphisms and susceptibility to carotid atherosclerosis in a Chinese Han population","volume":"633","author":"Chu","year":"2017","journal-title":"Gene"},{"key":"10.1016\/bs.acc.2019.04.002_bb0685","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1172\/JCI24061","article-title":"Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice","volume":"115","author":"Moore","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2019.04.002_bb0690","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000475934","article-title":"Measurement of aortic cell fluid-phase pinocytosis in vivo by flow cytometry","volume":"54","author":"Anzinger","year":"2017","journal-title":"J. Vasc. Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0695","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091892","article-title":"Critical role of the human ATP-binding cassette G1 transporter in cardiometabolic diseases","volume":"18","author":"Hardy","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2019.04.002_bb0700","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1194\/jlr.M800362-JLR200","article-title":"Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux","volume":"50","author":"Sankaranarayanan","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0705","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1194\/jlr.M500546-JLR200","article-title":"Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1","volume":"47","author":"Kobayashi","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0710","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/ATVBAHA.111.234872","article-title":"Genetic variation in ABCG1 and risk of myocardial infarction and ischemic heart disease","volume":"32","author":"Schou","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0715","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1161\/ATVBAHA.111.243519","article-title":"Human ATP-binding cassette G1 controls macrophage lipoprotein lipase bioavailability and promotes foam cell formation","volume":"32","author":"Olivier","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0720","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.atherosclerosis.2011.05.043","article-title":"A polymorphism in the ABCG1 promoter is functionally associated with coronary artery disease in a Chinese Han population","volume":"219","author":"Xu","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0725","doi-asserted-by":"crossref","first-page":"29993","DOI":"10.1074\/jbc.275.39.29993","article-title":"Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor","volume":"275","author":"Gu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0730","doi-asserted-by":"crossref","first-page":"32692","DOI":"10.1074\/jbc.274.46.32692","article-title":"Transport of lipids from high and low density lipoproteins via scavenger receptor-BI","volume":"274","author":"Stangl","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0735","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1194\/jlr.M500187-JLR200","article-title":"Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux","volume":"46","author":"Asztalos","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0740","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbalip.2006.12.004","article-title":"LDL particle subspecies are distinct in their capacity to mediate free cholesterol efflux via the SR-BI\/Cla-1 receptor","volume":"1771","author":"Treguier","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl A","key":"10.1016\/bs.acc.2019.04.002_bb0745","article-title":"Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches","volume":"19","author":"Chapman","year":"1998","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2019.04.002_bb0750","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1074\/jbc.275.13.9120","article-title":"Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection","volume":"275","author":"Gu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0755","doi-asserted-by":"crossref","first-page":"24976","DOI":"10.1074\/jbc.M402435200","article-title":"Glycine 420 near the C-terminal transmembrane domain of SR-BI is critical for proper delivery and metabolism of high density lipoprotein cholesteryl ester","volume":"279","author":"Parathath","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0760","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0022-2275(20)34274-7","article-title":"Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis","volume":"26","author":"Pomerantz","year":"1985","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0765","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3803\/EnM.2016.31.2.223","article-title":"High-density lipoprotein, lecithin: cholesterol acyltransferase, and atherosclerosis","volume":"31","author":"Ossoli","year":"2016","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"10.1016\/bs.acc.2019.04.002_bb0770","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1194\/jlr.R024513","article-title":"Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?","volume":"53","author":"Kunnen","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0775","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1210\/jc.2011-1846","article-title":"LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals","volume":"97","author":"Haase","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2019.04.002_bb0780","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1194\/P900038-JLR200","article-title":"Plasma levels of lecithin: cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study","volume":"51","author":"Holleboom","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0785","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cca.2018.02.006","article-title":"Lipoprotein lipase: biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases","volume":"480","author":"He","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2019.04.002_bb0790","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.atherosclerosis.2004.05.023","article-title":"Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease","volume":"176","author":"Sposito","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0795","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2003.11.065","article-title":"Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study","volume":"43","author":"Sposito","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0800","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.acc.2019.04.002_bb0805","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171642","article-title":"Associations between LPL gene polymorphisms and coronary artery disease: evidence based on an updated and cumulative meta-analysis","volume":"38","author":"Ma","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/bs.acc.2019.04.002_bb0810","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00041433-200304000-00010","article-title":"Hepatic lipase: a marker for cardiovascular disease risk and response to therapy","volume":"14","author":"Zambon","year":"2003","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0815","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1194\/jlr.R200008-JLR200","article-title":"Hepatic lipase: a pro- or anti-atherogenic protein?","volume":"43","author":"Jansen","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0820","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk","volume":"53","author":"Barter","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0825","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","article-title":"Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease","volume":"47","author":"Barter","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0830","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejphar.2015.05.061","article-title":"Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib","volume":"762","author":"Johns","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0835","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.atherosclerosis.2016.06.044","article-title":"HDL metrics, let's call the number thing off?","volume":"251","author":"Sposito","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0840","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.ATV.15.5.551","article-title":"The response-to-retention hypothesis of early atherogenesis","volume":"15","author":"Williams","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0845","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9150(98)00169-5","article-title":"In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin: cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase","volume":"141","author":"Chung","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0850","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0005-2760(90)90218-M","article-title":"Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma","volume":"1044","author":"Newnham","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.acc.2019.04.002_bb0855","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0022-2275(20)39962-4","article-title":"Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins","volume":"35","author":"Liang","year":"1994","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0860","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1074\/jbc.272.7.3953","article-title":"Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion","volume":"272","author":"Rye","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0865","doi-asserted-by":"crossref","first-page":"12867","DOI":"10.1021\/bi980828m","article-title":"Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction","volume":"37","author":"Lund-Katz","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/bs.acc.2019.04.002_bb0870","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00125-005-0088-0","article-title":"Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus","volume":"49","author":"de Vries","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/bs.acc.2019.04.002_bb0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.08.002","article-title":"Lipid transfer proteins: past, present and perspectives","volume":"209","author":"Quintao","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0880","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","article-title":"Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen risk and cardiovascular health study","volume":"121","author":"Ritsch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2019.04.002_bb0885","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2019.04.002_bb0890","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.amjcard.2010.03.057","article-title":"On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study)","volume":"106","author":"Khera","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0895","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0900","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HTRC Group","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0905","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0910","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2019.04.002_bb0915","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0022-2275(20)34314-5","article-title":"Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis","volume":"26","author":"Tall","year":"1985","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0920","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbalip.2011.06.013","article-title":"Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism","volume":"1821","author":"Albers","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.acc.2019.04.002_bb0925","doi-asserted-by":"crossref","first-page":"31850","DOI":"10.1074\/jbc.M205077200","article-title":"Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E","volume":"277","author":"Jiang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0930","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1194\/jlr.M001875","article-title":"Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis","volume":"51","author":"Bailey","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0935","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1021\/bi700833h","article-title":"Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles","volume":"46","author":"Vikstedt","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/bs.acc.2019.04.002_bb0940","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1074\/jbc.M800117200","article-title":"An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux","volume":"283","author":"Oram","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2019.04.002_bb0945","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s001250051009","article-title":"Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients","volume":"41","author":"Riemens","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/bs.acc.2019.04.002_bb0950","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s001250100630","article-title":"Influence of obesity and insulin sensitivity on phospholipid transfer protein activity","volume":"44","author":"Kaser","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/bs.acc.2019.04.002_bb0955","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.atherosclerosis.2009.08.048","article-title":"Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study","volume":"209","author":"Arsenault","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0960","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.atherosclerosis.2009.04.011","article-title":"Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography","volume":"207","author":"Cavusoglu","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0965","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/01.ATV.0000094433.98445.7F","article-title":"High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease","volume":"23","author":"Schlitt","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2019.04.002_bb0970","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1253\/circj.68.11","article-title":"Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases","volume":"68","author":"Yatsuya","year":"2004","journal-title":"Circ. J."},{"key":"10.1016\/bs.acc.2019.04.002_bb0975","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2007.04.046","article-title":"Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis","volume":"196","author":"Schgoer","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2019.04.002_bb0980","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1194\/jlr.M100349-JLR200","article-title":"Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia","volume":"43","author":"Oka","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0985","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jama.301.11.1131","article-title":"ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial","volume":"301","author":"Meuwese","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2019.04.002_bb0990","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2019.04.002_bb0995","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jacl.2013.03.003","article-title":"Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors","volume":"7","author":"Goldberg","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/bs.acc.2019.04.002_bb1000","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1124\/jpet.109.161232","article-title":"Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes","volume":"332","author":"Luo","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242319300289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242319300289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:37:36Z","timestamp":1758742656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242319300289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128174777"],"references-count":199,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2019.04.002","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}